EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A RARγ–SMARCA5 chromatin-remodeling axis stabilizes AR luminal programs and opposes lineage plasticity in prostate cancer

Sajad A Wani, Shahid Hussain iD, Khalid B Mir, Jaimie S Gray, Debasis Nayak, Hancong Tang, Lillian M Perez, Mark D Long, Manjunath Siddappa, Eva Corey, Peter S Nelson, Christopher J McCabe und 3 weitere

Nucleic Acids Research · 10.11.2026 · 54 (21)

DOI: 10.1093/nar/gkag1138 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 11.11.2026. Verfasst von Sajad A Wani und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmaceutics and Pharmacology, The Ohio State University, Columbus, OH 43210, United States. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Receptors, Retinoic Acid, Chromatin Assembly and Disassembly, Receptors, Androgen. Die Arbeit nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Prostate Cancer UK, Department of Defense Congressionally Directed Medical Research Programs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In prostate cancer (PCa), epigenomic mechanisms drive resistance to androgen receptor (AR) signaling inhibitors, such as enzalutamide (enza). We tested whether retinoic acid receptor gamma (RARγ) shapes the epigenome to direct AR transcription, promote luminal identity, and limit enza resistance. RARγ restoration in enza-resistant 22Rv1 cells induced a large RARγ complex containing its coactivator TACC1 and the chromatin remodeler ISWI ATPase SMARCA5. RARγ restoration expanded and redistributed the AR cistrome toward active promoters, enhancers, and unique super-enhancers and increased the overlap with H3K27ac. RARγ restoration also increased SMARCA5 promoter-proximal binding that overlapped with G2/M-enriched AR cistrome, linking AR redistribution to cell cycle-associated chromatin engagement, including at luminal genes. In 22Rv1 and LNCaP C4-2 (also enza-resistant), RARγ restoration directed the AR transcriptome toward luminal differentiation. A miR-96 antagomir (targeting RARγ) mirrored the impact of RARγ restoration. RARγ antagonized the actions of the master lineage regulator ONECUT2 at the cistrome and transcriptome level and these antagonized genes were significantly associated with alternative lineages in murine PCa models of lineage plasticity and enza responsiveness and lineage plasticity in human PCa cohorts. These findings identify RARγ as a regulator of a chromatin remodeling mechanism that sustains luminal AR programs and opposes therapeutic resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsReceptors, Retinoic AcidChromatin Assembly and DisassemblyReceptors, AndrogenChromosomal Proteins, Non-HistoneMaleHumansRetinoic Acid Receptor gammaCell Line, TumorGene Expression Regulation, NeoplasticSuper EnhancersDrug Resistance, NeoplasmAnimalsCell LineageMicroRNAsPromoter Regions, Genetic

Substanzen

Receptors, Retinoic AcidRetinoic Acid Receptor gammaReceptors, AndrogenChromosomal Proteins, Non-HistoneMicroRNAs

Autor:innen und Institutionen

  • Division of Pharmaceutics and Pharmacology, The Ohio State University, Columbus, OH 43210, United States.
  • Division of Cancer Biology, Cedars-Sinai Cancer, Los Angeles, CA 90048, United States.
  • Board of Governors Innovation Center, Department of Biomedical Sciences, Cedars-Sinai Health Sciences University, Los Angeles, CA 90048, United States.
  • Division of Cancer Therapeutics, Cedars-Sinai Cancer, Departments of Urology and Biomedical Sciences, Cedars-Sinai Health Sciences University, Los Angeles, CA 90048, United States.
  • Roswell Park Comprehensive Cancer Center, Elm and Carlton Streets, Buffalo, NY 14263, United States.
  • Department of Urology, University of Washington, Seattle, WA 98195, United States.

ORCID-Profile: Shahid Hussain, Moray J Campbell

Förderung

  • NCI NIH HHS
  • Prostate Cancer UK
  • Department of Defense Congressionally Directed Medical Research Programs
  • National Institute of Health Cancer Center
  • Ohio State University Comprehensive Cancer Center
  • Karmanos Cancer Institute
  • Prostate Cancer Foundation
  • NIH

Zitieren

APA

Wani, S. A., Hussain, S., Mir, K. B., Gray, J. S., Nayak, D., Tang, H., Perez, L. M., Long, M. D., Siddappa, M., Corey, E., Nelson, P. S., McCabe, C. J., Sucheston-Campbell, L. E., Freeman, M. R., & Campbell, M. J. (2026). A RARγ–SMARCA5 chromatin-remodeling axis stabilizes AR luminal programs and opposes lineage plasticity in prostate cancer. Nucleic Acids Research, 54(21). https://doi.org/10.1093/nar/gkag1138

Vancouver

Wani SA, Hussain S, Mir KB, Gray JS, Nayak D, Tang H, et al. A RARγ–SMARCA5 chromatin-remodeling axis stabilizes AR luminal programs and opposes lineage plasticity in prostate cancer. Nucleic Acids Research. 2026;54(21). doi:10.1093/nar/gkag1138

BibTeX
@article{Wani2026,
  author = {Wani, Sajad A and Hussain, Shahid and Mir, Khalid B and Gray, Jaimie S and Nayak, Debasis and Tang, Hancong and Perez, Lillian M and Long, Mark D and Siddappa, Manjunath and Corey, Eva and Nelson, Peter S and McCabe, Christopher J and Sucheston-Campbell, Lara E and Freeman, Michael R and Campbell, Moray J},
  title = {A RARγ–SMARCA5 chromatin-remodeling axis stabilizes AR luminal programs and opposes lineage plasticity in prostate cancer},
  journal = {Nucleic Acids Research},
  year = {2026},
  volume = {54},
  number = {21},
  doi = {10.1093/nar/gkag1138}
}
Kostenlos starten →